Researchers from MIT and Massachusetts General Hospital have developed an automated model that assesses dense breast tissue in mammograms—which is an independent risk factor for breast cancer—as reliably as expert radiologists.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
